TABLE 5.

Drug-related TEAEs by dosing phase^a

TEAE data	Low-dose cohortb			High-dose cohortc
	800 mg, day 1	400 mg, day 2	200 mg, day 2 to EOTd	1,600 mg, day 1	800 mg, day 2	400 mg, day 3 to EOT
n	11	10	8	12	11	11
Patients with drug-related TEAEs (no. [%])	3 (27.3)	2 (20.0)	2 (25.0)	3 (25.0)	1 (9.1)	6 (54.5)
Total no. of TEAEs	4	3	5	5	1	15
Most commonly reported AEs (no. [%])e
Cough	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (18.2)
Headache	1 (9.1)	1 (10.0)	0 (0)	0 (0)	0 (0)	2 (18.2)
Hypotension	0 (0)	1 (10.0)	1 (12.5)	0 (0)	0 (0)	0 (0)
Rash	0 (0)	0 (0)	1 (12.5)	1 (8.3)	0 (0)	1 (9.1)
Vertigo	1 (9.1)	1 (10.0)	0 (0)	0 (0)	0 (0)	0 (0)

^aTEAE, treatment-emergent adverse event.

^bIsavuconazole administered as a 200-mg once-daily maintenance regimen.

^cIsavuconazole administered as a 400-mg once-daily maintenance regimen.

^dEOT, end of treatment.

^eTEAEs were reported by ≥2 patients in either cohort.